CRISPR therapy for dyslipidemia.
The potential for gene editing and epigenetic therapy for the management of dyslipidemia appears to be well tolerated, and a number of agents with the potential for robust and durable changes to atherosclerotic lipid and lipoprotein risk factors are developed.